- Home
- CMMB vs ZBAI Comparison
CMMB vs ZBAI Comparison
Compare CMMB & ZBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CMMB | ZBAI |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Professional Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1M | 9.5M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | CMMB | ZBAI |
|---|---|---|
| Price | $1.57 | $6.60 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $26.50 | N/A |
| AVG Volume (30 Days) | ★ 57.9K | 6.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 101.67 | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $40.75 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.87 | $0.30 |
| 52 Week High | $3.86 | $11.94 |
Technical Indicators
Market Signals| Indicator | CMMB | ZBAI |
|---|---|---|
| Relative Strength Index (RSI) | 44.87 | 49.69 |
| Support Level | $1.40 | $5.66 |
| Resistance Level | $1.64 | $7.44 |
| Average True Range (ATR) | 0.13 | 0.64 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 47.06 | 51.65 |
Price Performance
Historical ComparisonAbout CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
About ZBAI ATIF Holdings Limited Ordinary Shares
ATIF Holdings Ltd is a consulting company. It provides financial consulting services to small and medium-sized enterprises. It operates in one operating segment, which is the consulting service business. The company prominently generated revenues from consulting services to its clients. Geographically, the maximum revenue is derived from Hong Kong.